May 6 (Reuters) - Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against re-election of three directors on the board of the COVID-19 vaccine maker.

Shah Capital, which currently owns a nearly 7.5% stake in Novavax, said it intends to vote against directors Richard Douglas, Margaret McGlynn and David Mott at the company's upcoming shareholder meeting in June.

"We believe that fresh perspectives are desperately needed in the boardroom to steer Novavax towards sustainable profitable growth," the hedge fund said in a statement.

Novavax did not immediately respond to a Reuters request for comment.

Shah Capital had previously expressed concerns about mismanagement of the Maryland-based biotech and nominated two of its own candidates for the board.

Shares of Novavax were down 1.2% at $4.87 in premarket trading.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)